[go: up one dir, main page]

WO2009089457A1 - Procédés pour produire de l'acide 3-hydroxypropionique et composés correspondants - Google Patents

Procédés pour produire de l'acide 3-hydroxypropionique et composés correspondants Download PDF

Info

Publication number
WO2009089457A1
WO2009089457A1 PCT/US2009/030607 US2009030607W WO2009089457A1 WO 2009089457 A1 WO2009089457 A1 WO 2009089457A1 US 2009030607 W US2009030607 W US 2009030607W WO 2009089457 A1 WO2009089457 A1 WO 2009089457A1
Authority
WO
WIPO (PCT)
Prior art keywords
activity
coa
polypeptide
alanine
nrrl
Prior art date
Application number
PCT/US2009/030607
Other languages
English (en)
Inventor
Alan Berry
Original Assignee
Novozymes A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novozymes A/S filed Critical Novozymes A/S
Publication of WO2009089457A1 publication Critical patent/WO2009089457A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
    • C12P7/42—Hydroxy-carboxylic acids

Definitions

  • the present invention relates to methods for producing 3-hydroxypropionic acid and compounds thereof.
  • Organic acids have long been used in the food, pharmaceutical, and textile industries, and more recently in the production of biodegradable plastics.
  • organic acids such as citric acid and lactic acid (also known as 2-hydroxypropanoic acid) are produced in large-scale today by microbial fermentation processes.
  • Other organic acids like fumaric acid and malic acid, can also be produced by microbial processes, but currently are not produced commercially in this manner because chemical synthesis from petroleum-derived precursors is more economical.
  • Some organic acids are also recognized as potential platform chemicals, or building blocks, which can be produced by fermentation from renewable feedstocks, and then further modified by chemical or enzymatic means to produce an array of other valuable industrial chemicals.
  • lactic acid which is produced by fermentation and then converted to ethyl lactate or polylactic acid.
  • Polylactic acid is a biodegradable plastic that provides an alternative to petroleum-based plastics and is expanding into many areas including textiles, medical implants, drug carriers, food packaging, and cosmetics.
  • organic acids that can be produced by fermentation and converted to other industrial compounds are succinic acid and 3- hydroxypropionic acid (also known as 3-hydroxypropanoic acid or beta- lactic acid and hereinafter referred to as 3HP).
  • Succinic acid can be converted, for example, to 1 ,4-butanediol or tetrahydrofuran.
  • 3HP can be converted, for example, to acrylic acid or 1 ,3-propanediol.
  • the present invention relates to improved methods for producing 3HP and compounds derived from 3HP in commercially relevant quantities using metabolically engineered E. coli strains.
  • the present invention relates to methods for producing 3HP, comprising: cultivating a metabolically engineered E. coli strain derived from a strain previously engineered for high lactic acid or L-alanine production in a cultivation medium.
  • Figure 1 shows a metabolic pathway for the production of 3-HP via lactate.
  • Figure 2 shows a metabolic pathway for the production of poly-3HP.
  • Figure 3 shows a metabolic pathway for the production of 3HP esters via lactate.
  • Figure 4 shows a metabolic pathway for the production of 3-HP via acetyl-CoA.
  • Figure 5 shows a metabolic pathway for the production of 3-HP, 3HP esters, poly-3HP, aery late, acrylate esters, and polyacrylate.
  • Figure 6 shows a metabolic pathway for the production of 3-HP via beta-alanine.
  • Figure 7 shows a metabolic pathway for the production of 3-HP via beta-alanine and malonate semialdehyde.
  • the present invention relates to methods for producing 3HP utilizing E. coli strains that have been engineered by redirecting metabolic pathways toward 3HP for high 3HP production.
  • E. coli strains are engineered to increase 3HP biosynthesis from glucose, sucrose, or other sugars via pyruvate through lactate in the presence of a functional IdhA gene by incorporating one or more (several) mutations and/or deletions in the genes adhE, ackA, frdA, pflB, poxB, alaD, and atpFH (Causey et al, 2004, Proc. Natl. Acad. Sci.
  • coli strains are engineered to increase 3HP biosynthesis via pyruvate through acetyl-CoA by incorporating one or more (several) mutations and/or deletions in the genes IdhA, alaD, adhE, ackA, frdA, pflB, poxB, and atpFH, and engineering the metabolic steps leading from pyruvate to 3HP to allow for unimpeded flow of intermediates from pyruvate to 3HP.
  • e. coli strains are engineered to increase 3HP biosynthesis from propionate through propionyl-CoA and acrylyl-CoA by engineering the metabolic steps leading from propionate to 3HP to allow for unimpeded flow of intermediates from propionate to 3HP.
  • E. coli strains are engineered to increase 3HP biosynthesis via phosphoenolpyruvate or pyruvate through beta-alanine and acrylyl-CoA by incorporating one or more (several) mutations and/or deletions in the genes IdhA, alaD, adhE, ackA, frdA, pflB, poxB, and atpFH, and engineering the metabolic steps leading from phosphoenolpyruvate or pyruvate to 3HP to allow for unimpeded flow of intermediates from phosphoenolpyruvate or pyruvate to 3HP.
  • E. coli strains are engineered to increase 3HP biosynthesis via phosphoenolpyruvate or pyruvate through beta-alanine and acrylyl-CoA by incorporating one or more (several) mutations and/or deletions in the genes IdhA, alaD, adhE, ackA, frdA, pflB, poxB, and atp
  • coli strains are engineered to increase 3HP biosynthesis via phosphoenolpyruvate or pyruvate through beta-alanine and malonate semialdehyde by incorporating one or more (several) mutations and/or deletions in the genes IdhA, alaD, adhE, ackA, frdA, pflB, poxB, and atpFH, and engineering the metabolic steps leading from phosphoenolpyruvate or pyruvate to 3HP to allow for unimpeded flow of intermediates from phosphoenolpyruvate to 3HP.
  • the methods of the present invention can also be used to produce other compounds derived from 3HP, such as 1,3-propanediol, acrylic acid, polymerized acrylate, esters of aery late, polymerized 3HP, and esters of 3HP.
  • lactate can be converted into lactyl-CoA with a polypeptide having CoA transferase activity (EC 2.8.3.1); the resulting lactyl-CoA can then be converted into acrylyl-CoA with a polypeptide (or multiple polypeptide complex such as an activated E2 alpha and E2 beta complex) having lactyl-CoA dehydratase activity (EC 4.2.1.54); the resulting acrylyl-CoA can then be converted into 3-hydroxypropionyl-CoA (3HP-CoA) with a polypeptide having 3-hydroxypropionyl-CoA dehydratase activity (EC 4.2.1.-); and finally, the resulting 3HP-CoA can be converted into 3HP with a polypeptide having CoA transferase activity or a polypeptide having 3-hydroxypropionyl-CoA hydrolase activity (EC 3.1.2.-), which may be a polypeptide having 3-hydroxyisobutryl- CoA hydrolase activity (EC 3.1.2.4).
  • lactate can be converted into lactyl-CoA with a polypeptide having CoA synthetase activity (EC 6.2.1.-); the resulting lactyl-CoA can then be converted into acrylyl-CoA with a polypeptide (or multiple polypeptide complex) having lactyl-CoA dehydratase activity; the resulting acrylyl-CoA can then be converted into 3HP-CoA with a polypeptide having 3-hydroxypropionyl-CoA dehydratase activity; and finally, the resulting 3HP-CoA can be converted into polymerized 3HP with a polypeptide having polyhydroxyacid synthase activity (EC 2.3.1.-).
  • lactate can be converted into lactyl-CoA with a polypeptide having CoA transferase activity or a polypeptide having lactyl-CoA synthetase activity; the resulting lactyl-CoA can then be converted into acrylyl-CoA with a polypeptide (or multiple polypeptide complex) having lactyl-CoA dehydratase activity; the resulting acrylyl-CoA can then be converted into 3HP-CoA with a polypeptide having 3-hydroxypropionyl-CoA dehydratase activity; the resulting 3HP-CoA can then be converted into 3HP with a polypeptide having CoA transferase activity or a polypeptide having 3-hydroxypropionyl-CoA hydrolase activity, which may be a polypeptide having 3-hydroxyisobutryl-CoA hydrolase activity; and finally the resulting 3HP can be converted into an ester of 3HP with a polypeptide having lipase activity (EC 3.1.1.-).
  • acetyl-CoA can be converted into malonyl-CoA with a polypeptide having acetyl-CoA carboxylase activity (EC 6.4.1.2); and the resulting malonyl-CoA can then be converted into 3HP with a polypeptide or polypeptides having malonyl-CoA reductase activity (EC 1.1.1 and 1.2.1).
  • Polypeptides having malonyl-CoA reductase activity can use NADPH as a co- factor.
  • polypeptides having malonyl-CoA reductase activity can use NADH as a co-factor.
  • Such polypeptides can be obtained by converting a polypeptide that has malonyl-CoA reductase activity and uses NADPH as a cofactor into a polypeptide that has malonyl-CoA reductase activity and uses NADH as a cofactor. Any method can be used to convert a polypeptide that uses NADPH as a cofactor into a polypeptide that uses NADH as a cofactor such as those described Eppink et al., 1999, J. MoI.
  • propionate can be converted into propionyl-CoA with a polypeptide having CoA synthetase activity; the resulting propionyl-CoA can then be converted into acrylyl-CoA with a polypeptide having dehydrogenase activity and finally the resulting acrylyl-CoA can be converted into (1) acrylate with a polypeptide having CoA transferase activity or CoA hydrolase activity, (2) 3HP-CoA with a polypeptide having 3HP dehydratase activity (also referred to as acrylyl-CoA hydratase or simply hydratase), or (3) polymerized acrylate with a polypeptide having polyhydroxyacid synthase activity.
  • the resulting acrylate can be converted into an ester of acrylate with a polypeptide having lipase activity.
  • the resulting 3HP-CoA can be converted into (1) 3HP with a polypeptide having CoA transferase activity or a polypeptide having 3-hydroxypropionyl-CoA hydrolase activity (EC 3.1.2.-), which may be a polypeptide having 3-hydroxyisobutyryl-CoA hydrolase activity (EC 3.1.2.4), or (2) polymerized 3HP with a polypeptide having polyhydroxyacid synthase activity (EC 2.3.1.-).
  • PEP phosphoenolpyruvate
  • Carboxylation of PEP to oxaloacetate can be catalyzed by a polypeptide having PEP carboxylase activity (EC 4.1.1.31), a polypeptide having PEP carboxylase activity (EC 4.1.1.49), or a polypeptide having PEP transcarboxylase activity (EC 4.1.1.-).
  • Pyruvate generated from PEP by a polypeptide having pyruvate kinase activity (EC 2.7.1.40) can also be converted to oxaloacetate by a polypeptide having pyruvate carboxylase activity (EC 6.4.1.1).
  • Oxaloacetate generated either from PEP or pyruvate can act as a precursor for production of aspartic acid. This conversion can be carried out by a polypeptide having aspartate aminotransferase activity (EC 2.6.1.1), which transfers an amino group from an amino donor such as glutamate to oxaloacetate. The decarboxylation of aspartate to beta-alanine is catalyzed by a polypeptide having aspartate decarboxylase activity (EC 4.1.11).
  • Pyruvate generated from PEP can be converted to alpha-alanine by a polypeptide having alanine dehydrogenase activity (EC 1.4.1.1) (Zhang et a/., 2007, Appl Microbiol Biotechnol. 77:355-366; WO 2003/062173) or a polypeptide having alanine aminotransferase activity (EC 2.6.1.2).
  • Alpha-alanine produced by alanine dehydrogenase, alanine aminotransferase, or another polypeptide capable of converting pyruvate to alpha-alanine can then be converted to beta-alanine by a polypeptide having alanine 2,3-aminomutase activity (WO 2003/062173).
  • beta-alanine can be accomplished by polypeptides having enzyme activity native (endogenous) to the E. coli strain that convert PEP or pyruvate to beta-alanine, or these conversions can be accomplished recombinantly using known polypeptides such as polypeptides having PEP carboxylase activity (EC 4.1.1.31), aspartate aminotransferase activity (EC 2.6.1.1), aspartate decarboxylase activity (EC 4.1.1.11), alanine dehydrogenase activity (EC 1.4.1.1), alanine aminotransferase activity (EC 2.6.1.2), and alanine 2,3-aminomutase activity .
  • polypeptides having PEP carboxylase activity EC 4.1.1.31
  • aspartate aminotransferase activity EC 2.6.1.1
  • aspartate decarboxylase activity EC 4.1.1.11
  • alanine dehydrogenase activity EC 1.4.1.1
  • beta-alanine produced by any of the biosynthetic routes described above can be converted to 3HP by two possible pathways.
  • first pathway ( Figure 6) beta-alanine can be converted into beta-alanyl-CoA with a polypeptide having CoA transferase activity (EC 2.8.3.-); the resulting beta-alanyl-CoA can then be converted into acrylyl-CoA with a polypeptide having beta-alanyl-CoA ammonia lyase activity; the resulting acrylyl-CoA can then be converted into 3HP-CoA with a polypeptide having 3HP-CoA dehydratase activity; and finally the resulting 3HP-CoA can be converted into 3HP with a polypeptide having CoA transferase activity (EC 2.8.3.-).
  • 3HP can be made from beta-alanine by first converting beta-alanine to malonate semialdehyde with a polypeptide having beta- alanine aminotransferase activity, which may be a polypeptide having 4-aminobutyrate aminotransferase activity (EC 2.6.1.19); and the resulting malonate semialdehyde can then be converted into 3HP with a polypeptide having 3HP dehydrogenase activity, which may be a polypeptide having 3-hydroxyisobutyrate dehydrogenase activity (EC 1.1.1.31).
  • Each step provided in the pathways shown in Figures 1-7 can be performed in vivo (within a cell) or in vitro (outside a cell). Additionally, the organic acid products can be generated through a combination of in vivo synthesis and in vitro synthesis. Moreover, the in vitro synthesis step, or steps, can be via chemical reaction or enzymatic reaction.
  • a cellular extract of an engineered E. coli strain described herein comprising polypeptides having the indicated enzyme activities, or a combination thereof can be used to perform the steps described in Figure 1-7.
  • chemical treatments can be used to perform one or more conversions provided in Figures 1-7.
  • acrylyl-CoA can be converted into acrylate by hydrolysis.
  • Other chemical treatments include, without limitation, transesterification to convert acrylate into an acrylate ester.
  • intermediate chemical products can be starting points.
  • beta alanine can be introduced into a fermentation broth.
  • the exogenously supplied beta-alanine can be imported into the E. coli cells and converted to 3HP by either of the pathways shown in Figures 6 and 7.
  • Other useful intermediate chemical starting points can include propionic acid, acrylic acid, lactic acid, and pyruvic acid.
  • the polypeptides having enzyme activity described herein can be produced individually in an E. coli strain, in combination in an E. coli strain, or individually and in combination in two or more E. coli strains.
  • the polypeptides having enzyme activity and polynucleotides thereof may be native or foreign (heterologous) to the E. coli strain.
  • the polypeptides having a particular enzyme activity can be a polypeptide that is either naturally-occurring or non-naturally-occurring.
  • a naturally-occurring polypeptide is any polypeptide having an amino acid sequence as found in nature, including wild-type and polymorphic polypeptides.
  • Such naturally-occurring polypeptides can be obtained from any species including, without limitation, animal (e.g., mammalian), plant, fungal, and bacterial species.
  • a non-naturally-occurring polypeptide is any polypeptide having an amino acid sequence that is not found in nature.
  • a non-naturally-occurring polypeptide can be a mutated version of a naturally-occurring polypeptide, or an engineered polypeptide.
  • a non-naturally-occurring polypeptide having alanine 2,3-aminomutase activity can be a mutated version of a naturally-occurring polypeptide having lysine 2,3- aminomutase activity (WO 2003/062173).
  • a polypeptide can be mutated by, for example, one or more (several) amino acid additions, deletions, substitutions, or combinations thereof.
  • polypeptide is not meant herein to refer to a specific length of the encoded product and, therefore, encompasses peptides, oligopeptides, and proteins.
  • polypeptide also encompasses hybrid polypeptides, which comprise a combination of partial or complete polypeptide sequences obtained from at least two different polypeptides wherein one or more may be heterologous to the E. coli strain. Polypeptides further include naturally occurring allelic and engineered variations of a polypeptide.
  • the term "foreign polypeptide” is defined herein as a polypeptide that is not native to the host cell; a native polypeptide in which structural modifications have been made to alter the native polypeptide, e.g., the protein sequence of the native polypeptide; or a native polypeptide whose expression is quantitatively altered as a result of a manipulation of the DNA encoding the polypeptide by recombinant DNA techniques, e.g., a stronger promoter.
  • the polypeptide may be an engineered variant of any polypeptide.
  • Polypeptides having enzyme activity useful for practicing the present invention include, but are not limited to, 3-hydroxypropionyl-CoA dehydratase, 3- hydroxypropionyl-CoA hydratase, CoA transferases, lactyl-CoA dehydratase, 3-hydroxypropionyl-CoA hydrolase, 3-hydroxyisobutryl-CoA hydrolase, polyhydroxyacid synthase, CoA synthetase, malonyl-CoA reductase, beta-alanine ammonia lyase, lipase, PEP carboxylase, PEP carboxylase, PEP transcarboxylase, pyruvate kinase, pyruvate carboxylase, beta-alanyl-CoA ammonia lyase, 3HP-CoA dehydratase, beta- alanine aminotransferase, 4-aminobutyrate aminotransferase, 3HP dehydrogenase, 3- hydroxyiso
  • polypeptides having enzyme activity as well as polynucleotides thereof can be obtained from various species including, without limitation, Acidianus brierleyi, Candida rugosa, Candida tropicalis, Chloroflexus aurantiacus, Clostridium propionicum, Clostridium kluyveri, Comamonas acidororans, Escherichia coli, Chloroflexus aurantiacus, Candida rugosa, Megasphaera elsdenii, Pseudomonas fluorescens, Ps ⁇ udomonas oleovorans, Ralstonia eutropha, Rhodobacter capsulates, Rhodobacter sphaeroides, Rhodospirillum rubrum, Saccharomyces cervisiae, Salmonella enterica, and Sulfolobus metacillus. See, for example, WO 2002/42418.
  • polypeptides having CoA transferase activity as well as polynucleotides thereof are obtained from Megasphaera elsdenii, Clostridium propionicum, Clostridium kluyveri, and Escherichia coli.
  • a polynucleotide that encodes a polypeptide having CoA transferase activity can be obtained from
  • polypeptides (or the polypeptides of a multiple polypeptide complex such as an activated E2 alpha and E2 beta complex) having lactyl- CoA dehydratase activity as well as polynucleotides thereof can be obtained from Megasphaera elsdenii and Clostridium propionicum.
  • a polynucleotide encoding an E1 activator, an E2 alpha subunit, and an E2 beta subunit that can form a multiple polypeptide complex having lactyl-CoA dehydratase activity can be obtained from Megasphaera elsdenii.
  • polypeptides having 3-hydroxypropionyl-CoA dehydratase activity as well as polynucleotides thereof can be obtained from Chloroflexus aurantiacus, Candida rugosa, Rhodospirillum rubrum, and Rhodobacter capsulates.
  • polypeptides having 3-hydroxypropionyl-CoA hydrolase activity as well as polynucleotides thereof can be obtained from Candida rugosa.
  • polypeptides having 3-hydroxyisobutryl-CoA hydrolase activity as well as polynucleotides thereof can be obtained from Pseudomonas fluorescens, rattus, and homo sapiens.
  • polypeptides having CoA synthetase activity as well as polynucleotides thereof can be obtained from Escherichia coli, Rhodobacter sphaeroides, Saccharomyces cervisiae, and Salmonella enterica.
  • polypeptides having polyhydroxyacid synthase activity as well as polynucleotides thereof can be obtained from Comamonas acidororans, Pseudomonas oleovorans, Ralstonia eutropha, and Rhodobacter sphaeroides.
  • polypeptides having lipase activity as well as polynucleotides thereof can be obtained from Candida albicans, Candida rugosa, and Candida tropicalis.
  • polypeptides having acetyl-CoA carboxylase activity as well as polynucleotides thereof can be obtained from Escherichia coli and Chloroflexus aurantiacus.
  • polypeptides having malonyl-CoA reductase activity as well as polynucleotides thereof can be obtained from Acidianus brierleyi, Chloroflexus aurantiacus, and Sulfolobus metacillus.
  • polypeptides having propionyl-CoA hydrolase activity as well as polynucleotides thereof can be obtained from Chloroflexus aurantiacus.
  • Chloroflexus aurantiacus cells can be used as a source of genomic DNA for cloning a polynucleotide encoding a polypeptide having CoA synthetase activity, dehydratase activity, and dehydrogenase activity (propionyl- CoA synthetase) and a polynucleotide encoding a polypeptide having 3- hydroxypropionyl-CoA dehydratase activity (also referred to as acrylyl-CoA hydratase activity).
  • polypeptides having acrylyl-CoA hydrolase activity as well as polynucleotides thereof can be obtained from Chloroflexus aurantiacus.
  • Chloroflexus aurantiacus cells ATCC 29365
  • ATCC 29365 can be used as a source of genomic DNA for cloning a polynucleotide encoding a polypeptide having 3- hydroxypropionyl-CoA dehydratase activity (also referred to as acrylyl-CoA hydratase activity).
  • PCR polymerase chain reaction
  • the cloning procedures may involve excision and isolation of a desired nucleic acid fragment comprising the nucleic acid sequence encoding the polypeptide, insertion of the fragment into a vector molecule, and incorporation of the recombinant vector into the mutant E. coli cell where multiple copies or clones of the nucleic acid sequence will be replicated.
  • the polynucleotide may be of genomic, cDNA, semisynthetic, synthetic origin, or any combinations thereof.
  • nucleotide sequence or a subsequence thereof, as well as the amino acid sequence or a fragment thereof, of a known enzyme may be used to design nucleic acid probes to identify and clone DNA encoding polypeptides having the same or similar enzyme activity from strains of different genera or species according to methods well known in the art.
  • probes can be used for hybridization with the genomic or cDNA of the genus or species of interest, following standard Southern blotting procedures, in order to identify and isolate the corresponding gene therein.
  • probes can be considerably shorter than the entire sequence, but should be at least 14, preferably at least 25, more preferably at least 35, and most preferably at least 70 nucleotides in length.
  • the nucleic acid probe is at least 100 nucleotides in length.
  • the nucleic acid probe may be at least 200 nucleotides, preferably at least 300 nucleotides, more preferably at least 400 nucleotides, or most preferably at least 500 nucleotides in length.
  • Even longer probes may be used, e.g., nucleic acid probes that are preferably at least 600 nucleotides, more preferably at least 700 nucleotides, even more preferably at least 800 nucleotides, or most preferably at least 900 nucleotides in length.
  • Both DNA and RNA probes can be used.
  • the probes are typically labeled for detecting the corresponding gene (for example, with 32 P, 3 H, 35 S, biotin, or avidin). Such probes are encompassed by the present invention.
  • a genomic DNA or cDNA library prepared from such other strains may, therefore, be screened for DNA that hybridizes with the probes and encodes a polypeptide having enzyme activity.
  • Genomic or other DNA from such other strains may be separated by agarose or polyacrylamide gel electrophoresis, or other separation techniques.
  • DNA from the libraries or the separated DNA may be transferred to and immobilized on nitrocellulose or other suitable carrier material.
  • the carrier material is preferably used in a Southern blot.
  • hybridization indicates that the nucleotide sequence hybridizes to a labeled nucleic acid probe under very low to very high stringency conditions. Molecules to which the nucleic acid probe hybridizes under these conditions can be detected using, for example, X-ray film.
  • very low to very high stringency conditions are defined as prehybridization and hybridization at 42°C in 5X SSPE, 0.3% SDS, 200 ⁇ g/ml sheared and denatured salmon sperm DNA, and either 25% formamide for very low and low stringencies, 35% formamide for medium and medium-high stringencies, or 50% formamide for high and very high stringencies, following standard Southern blotting procedures for 12 to 24 hours optimally.
  • the carrier material is finally washed three times each for 15 minutes using 2X SSC, 0.2% SDS preferably at 45°C (very low stringency), more preferably at 50°C (low stringency), more preferably at 55°C (medium stringency), more preferably at 60°C (medium-high stringency), even more preferably at 65°C (high stringency), and most preferably at 7O°C (very high stringency).
  • stringency conditions are defined as prehybridization, hybridization, and washing post- hybridization at about 5°C to about 10°C below the calculated T m using the calculation according to Bolton and McCarthy (1962, Proceedings of the National Academy of
  • the carrier material is washed once in 6X SCC plus 0.1% SDS for 15 minutes and twice each for 15 minutes using 6X SSC at 5°C to 10°C below the calculated T m .
  • Polypeptide sequencing techniques can also be used to identify and obtain a polynucleotide that encodes a polypeptide having enzyme activity.
  • a purified polypeptide can be separated by gel electrophoresis, and its amino acid sequence determined by, for example, amino acid microsequencing techniques. Once determined, the amino acid sequence can be used to design degenerate oligonucleotide primers. The degenerate oligonucleotide primers can then be used to obtain the polynucleotide encoding the polypeptide by PCR. Ex. pression cloning techniques also can be used to identify and obtain such a polynucleotide.
  • a substrate known to interact with a particular enzymatic polypeptide can be used to screen a phage display library containing that enzymatic polypeptide.
  • Phage display libraries can be generated as described elsewhere (Burritt er a/., 1990, Anal. Biochem. 238: 1-13), or can be obtained from commercial suppliers such as Novagen (Madison, Wl, USA).
  • a polynucleotide encoding a polypeptide having enzyme activity can be mutated using common molecular cloning techniques (e.g., site-directed mutagenesis).
  • Possible mutations include, without limitation, a substitution, deletion, and/or insertion of one or more (or several) amino acids of the polypeptide such that the physico-chemical properties of the polypeptides are altered.
  • amino acid changes may improve the thermal stability of the polypeptide, increase specific activity, improve or alter the substrate specificity, change the pH optimum, and the like.
  • Essential amino acids in the parent polypeptide can be identified according to procedures known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham and Wells, 1989, Science 244: 1081-1085). In the latter technique, single alanine mutations are introduced at every residue in the molecule, and the resultant mutant molecules are tested for enzyme activity to identify amino acid residues that are critical to the activity of the molecule. See also, Hilton et ai, 1996, J. Biol. Ch ⁇ m. 271: 4699-4708.
  • the active site of the enzyme or other biological interaction can also be determined by physical analysis of structure, as determined by such techniques as nuclear magnetic resonance, crystallography, electron diffraction, or photoaffinity labeling, in conjunction with mutation of putative contact site amino acids. See, for example, de Vos et ai, 1992, Science 255: 306-312; Smith et al., 1992, J. MoI. Biol. 224: 899-904; Wlodaver et ai, 1992, FEBS Lett. 309: 59-64.
  • the identities of essential amino acids can also be inferred from analysis of identities with polypeptides that are related to a polypeptide.
  • Single or multiple amino acid substitutions, deletions, and/or insertions can be made and tested using known methods of mutagenesis, recombination, and/or shuffling, followed by a relevant screening procedure, such as those disclosed by Reidhaar-Olson and Sauer, 1988, Science 241 : 53-57; Bowie and Sauer, 1989, Proc. Natl. Acad. Sd. USA 86: 2152-2156; WO 95/17413; or WO 95/22625.
  • Other methods that can be used include error-prone PCR, phage display (e.g., Lowman et a/., 1991 , Biochem. 30: 10832-10837; U.S. Patent No. 5,223,409; WO 92/06204), and region-directed mutagenesis (Derbyshire er a/. , 1986, Gene 46: 145; Ner ef ai., 1988, DNA 7: 127).
  • Mutagenesis/shuffling methods can be combined with high-throughput, automated screening methods to detect activity of cloned, mutagenized polypeptides expressed by host cells (Ness et a/., 1999, Nature Biotechnology 17: 893-896).
  • Mutagenized DNA molecules that encode active polypeptides can be recovered from the host cells and rapidly sequenced using standard methods in the art. These methods allow the rapid determination of the importance of individual amino acid residues in a polypeptide of interest, and can be applied to polypeptides of unknown structure.
  • a polypeptide can have three functional domains: a domain having CoA synthatase activity, a domain having 3HP-CoA dehydratase activity, and a domain having CoA-reductase activity.
  • Such polypeptides can be selectively modified by mutating and/or deleting domains such that one or two of the enzyme activities are reduced. Reducing the dehydratase activity can cause acrylyl-CoA to be obtained from propionyl-CoA. The acrylyl-CoA then can be contacted with a polypeptide having CoA hydrolase activity to produce acrylate from propionate (Figure 5).
  • acrylyl-CoA can be obtained from 3HP by using, for example, such a polypeptide having reduced CoA reductase activity.
  • a polynucleotide encoding a polypeptide having enzyme activity may be manipulated in a variety of ways to provide for expression of the polynucleotide in an E. coli host cell. The construction of nucleic acid constructs and recombinant expression vectors for the polynucleotide encoding a polypeptide of interest can be accomplished as described herein.
  • Nucleic acid constructs can be prepared comprising an isolated polynucleotide encoding a polypeptide having enzyme activity operably linked to one or more (several) control sequences that direct the expression of the coding sequence in E. coli under conditions compatible with the control sequences.
  • the isolated polynucleotide may be manipulated to provide for expression of the polypeptide. Manipulation of the polynucleotide's sequence prior to its insertion into a vector may be desirable or necessary depending on the expression vector.
  • the techniques for modifying polynucleotide sequences utilizing recombinant DNA methods are well known in the art.
  • the control sequence may be an appropriate promoter sequence, a nucleotide sequence that is recognized by a host cell for expression of a polynucleotide encoding a polypeptide of the present invention.
  • the promoter sequence contains transcriptional control sequences that mediate the expression of the polypeptide.
  • the promoter may be any nucleotide sequence that shows transcriptional activity in the host cell of choice including mutant, truncated, and hybrid promoters, and may be obtained from genes encoding extracellular or intracellular polypeptides either homologous or heterologous to the host cell.
  • suitable promoters for directing transcription of the nucleic acid constructs, especially in an E. coli host cell are the lac promoter (Gronenborn, 1976, MoI.
  • the control sequence may also be a suitable transcription terminator sequence, a sequence recognized by a host cell to terminate transcription.
  • the terminator sequence is operably linked to the 3' terminus of the nucleotide sequence encoding the polypeptide. Any terminator that is functional in an £ coli cell may be used in the present invention. It may also be desirable to add regulatory sequences that allow regulation of the expression of the polypeptide relative to the growth of the host cell. Examples of regulatory systems are those that cause the expression of the gene to be turned on or off in response to a chemical or physical stimulus, including the presence of a regulatory compound. Regulatory systems in prokaryotic systems include the lac, tac, and trp operator systems.
  • Recombinant expression vectors can be prepared comprising a polynucleotide described herein, a promoter, and transcriptional and translational stop signals.
  • the various nucleic acids and control sequences described herein may be joined together to produce a recombinant expression vector that may include one or more (several) convenient restriction sites to allow for insertion or substitution of the nucleotide sequence encoding the polypeptide at such sites.
  • a polynucleotide sequence may be expressed by inserting the nucleotide sequence or a nucleic acid construct comprising the sequence into an appropriate vector for expression.
  • the coding sequence is located in the vector so that the coding sequence is operably linked with the appropriate control sequences for expression.
  • the recombinant expression vector may be any vector (e.g., a plasmid or bacteriophage) that can be conveniently subjected to recombinant DNA procedures and can bring about expression of the nucleotide sequence.
  • the choice of the vector will typically depend on the compatibility of the vector with the E. coti into which the vector is to be introduced.
  • the vectors may be linear or closed circular plasmids.
  • the vector may be an autonomously replicating vector, i.e., a vector that exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g., a plasmid, an extrachromosomal element, a minichromosome, or an artificial chromosome.
  • the vector may contain any means for assuring self- replication.
  • the vector may be one that, when introduced into the host cell, is integrated into the genome and replicated together with the chromosome(s) into which it has been integrated.
  • a single vector or plasmid or two or more vectors or plasmids that together contain the total DNA to be introduced into the genome of the host cell, or a transposon may be used.
  • the vectors preferably contain one or more (several) selectable markers that permit easy selection of transformed, transfected, transduced, or the like cells.
  • a selectable marker is a gene the product of which provides for biocide or viral resistance, resistance to heavy metals, prototrophy to auxotrophs, and the like.
  • Examples of bacterial selectable markers are markers that confer antibiotic resistance such as ampicillin, kanamycin, chloramphenicol, or tetracycline resistance.
  • the vectors preferably contain an element(s) that permits integration of the vector into the host cell's genome or autonomous replication of the vector in the cell independent of the genome.
  • the vector may rely on the polynucleotide's sequence encoding the polypeptide or any other element of the vector for integration into the genome by homologous or nonhomologous recombination.
  • the vector may contain additional nucleotide sequences for directing integration by homologous recombination into the genome of the host cell at a precise location(s) in the chromosome(s).
  • the integrational elements should preferably contain a sufficient number of nucleic acids, such as 100 to 10,000 base pairs, preferably 400 to 10,000 base pairs, and most preferably 800 to 10,000 base pairs, which have a high degree of identity to the corresponding target sequence to enhance the probability of homologous recombination.
  • the integrational elements may be any sequence that is homologous with the target sequence in the genome of the host cell.
  • the integrational elements may be non-encoding or encoding nucleotide sequences.
  • the vector may be integrated into the genome of the host cell by non-homologous recombination.
  • the vector may further comprise an origin of replication enabling the vector to replicate autonomously in the host cell in question.
  • the origin of replication may be any plasmid replicator mediating autonomous replication that functions in a cell.
  • the term "origin of replication" or "plasmid replicator is defined herein as a nucleotide sequence that enables a plasmid or vector to replicate in vivo. Ex. amples of bacterial origins of replication are the origins of replication of plasmids pBR322, pUC19, pACYC177, and pACYC184 permitting replication in E. coli.
  • More than one copy of a polynucleotide encoding a polypeptide having enzyme activity may be inserted into a host cell to increase production of the gene product.
  • An increase in the copy number of the polynucleotide can be obtained by integrating at least one additional copy of the sequence into the host cell genome or by including an amplifiable selectable marker gene with the polynucleotide where cells containing amplified copies of the selectable marker gene, and thereby additional copies of the polynucleotide, can be selected for by cultivating the cells in the presence of the appropriate selectable agent.
  • the E. coli cells described herein can contain a single copy, or multiple copies (e.g., about 5, 10, 20, 35, 50, 75, 100 or 150 copies), of a particular polynucleotide.
  • the host cells are E. coli strains that have been engineered to redirect a metabolic pathway to production of 3HP or a compound derived from 3HP in commercial relevant quantities.
  • the metaboljcally engineered E. coli strains preferably have overcome (1) osmotic stress caused by high concentrations of substrates and/or products and (2) the toxicity of high concentrations of products.
  • a metabolically engineered E. coli strain contains one or more foreign polynucleotides that encode polypeptides necessary to perform one or more of the steps shown in any of Figures 1-7.
  • Such cells can contain any number of foreign polynucleotides.
  • the genetically modified E. coli cells are preferably capable of producing 3HP when grown under a variety of fermentation conditions, so that a high yield of 3HP results from relatively inexpensive raw products such as glucose or sucrose.
  • the metabolically engineered E. coli strains may also have reduced polypeptide activity.
  • reduced polypeptide activity refers to a lower level of activity than that measured in a comparable cell of the same species.
  • a particular E. coli strain lacking an enzyme activity is considered to have reduced enzyme activity if a comparable E. coli strain has at least some enzyme activity.
  • a cell can have the activity of any type of polypeptide reduced including, without limitation, enzymes, transcription factors, transporters, receptors, signal molecules, and the like.
  • a cell can contain a foreign polynucleotide that disrupts a regulatory and/or coding sequence of a polypeptide having pyruvate decarboxylase activity or alcohol dehydrogenase activity.
  • Disrupting pyruvate decarboxylase and/or alcohol dehydrogenase expression can lead to the accumulation of lactate as well as products produced from lactate such as 3HP, 1 ,3-propanediol, acrylic acid, polyacrylate, acrylate esters, 3HP esters, and poly-3HP.
  • Reduced polypeptide activities can be the result of lower polypeptide concentration, lower specific activity of a polypeptide, or combinations thereof. Any method known in the art can be used to make a cell having reduced polypeptide activity.
  • a cell having reduced activity of a polypeptide can be identified using any method known in the art.
  • enzyme activity assays can be used to identify cells having a reduced enzyme activity. See Enzyme Nomenclature, Academic Press, Inc., New York, 2007.
  • Escherichia coli strains useful in the present invention include, but are not limited to, SZ32, SZ37, SZ40, SZ58, SZ63, LY52, SZ110, SZ132, SZ136, SZ162, SZ186, SZ194, TG102, TG103, TG105, TG106, TG107, TG108, TG112, TG113, TG114, TG128, TG129, TG130, XZ103, XZ104, XZ105, XZ106, XZ107, XZ108, XZ109, XZ110, XZ111 , XZ112, XZ113, XZ115, XZ121 , XZ123,
  • Strains XZ103, XZ104, XZ105, XZ106, XZ107, XZ108, XZ109 and XZ110 were obtained from the high lactic acid-producing strain SZ194 by replacing the native D- lactate dehydrogenase gene with the alaD (alanine dehydrogenase) gene from Geobacillus stearothermophilus, thereby replacing lactic acid production with L-alanine production (Zhang et al., 2007).
  • strains XZ111 , XZ112, XZ113, XZ115, XZ121 , XZ123, XZ126, XZ129, XZ130, XZ131 and XZ132 were obtained from strain XZ105 for improved alanine production through additional metabolic engineering and metabolic evolution as described by Zhang et al., 2007, supra.
  • E. coli hosts useful in the present invention are available from the Agricultural Research Service Culture Collection, 1815 N. University Street, Peoria, IL, USA.
  • the accession numbers are as follows: NRRL B- 30861 (SZ 132), NRRL B-30862 (SZ186), NRRL B-30863 (SZ194), NRRL B-30864 (TG103), NRRL B-30921 (TG102), NRRL B- 30922 (TG105), NRRL B-30923 (TG106), NRRL B-30924 (TG107), NRRL B-30925 (TG108), NRRL B-30926 (TG112), NRRL B-30927 (TG113), NRRL B-30928 (TG114), NRRL B-30962 (TG128), NRRL B-30963 (TG129), and NRRL B-30964 (TG130).
  • the metabolically engineered E. coli strain comprises one or more (several) mutations and/or deletions in the
  • the native lactate dehydrogenase gene is inactivated.
  • the native lactate dehydrogenase gene is replaced with the alaD (alanine dehydrogenase) gene from Geobacillus stearothermophilus to replace lactate production with alanine production.
  • the £ coli strain is metabolically engineered to increase 3HP biosynthesis from glucose, sucrose, or other sugars via pyruvate through lactate in the presence of a functional IdhA gene by incorporating one or more (several) mutations and/or deletions in the genes adhE, ackA, frdA, pflB, poxB, alaD, and atpFH (Causey et at., 2004, Proc. Natl. Acad. Sci.
  • the £ coli strain is metabolically engineered to increase 3HP biosynthesis via pyruvate through acetyl-CoA by incorporating one or more (several) mutations and/or deletions in the genes IdhA, alaD, adhE, ackA, frdA, pflB, poxB, and atpFH, and engineering the metabolic steps leading from pyruvate to 3HP to allow for unimpeded flow of intermediates from pyruvate to 3HP.
  • the £ coli strain is metabolically engineered to increase 3HP biosynthesis via propionate through propionyl-CoA and acrylyl-CoA by engineering the metabolic steps leading from propionate to 3HP to allow for unimpeded flow of intermediates from propionate to 3HP.
  • the E.. coli strain is metabolically engineered to increase 3HP biosynthesis via phosphoenolpyruvate or pyruvate through beta-alanine and acrylyl-CoA by incorporating one or more (several) mutations and/or deletions in the genes IdhA, alaD, adhE, ackA, frdA, pflB, poxB, and atpFH, and engineering the metabolic steps leading from phosphoenolpyruvate or pyruvate to 3HP to allow for unimpeded flow of intermediates from phosphoenolpyruvate or pyruvate to 3HP.
  • the £ coli strain is metabolically engineered to increase 3HP biosynthesis via phosphoenolpyruvate or pyruvate through beta-alanine and malonate semialdehyde by incorporating one or more (several) mutations and/or deletions in the genes IdhA, alaD, adhE, ackA, frdA, pflB, poxB, and atpFH, and engineering the metabolic steps leading from phosphoenolpyruvate or pyruvate to 3HP to allow for unimpeded flow of intermediates from phosphoenolpyruvate or pyruvate to 3HP.
  • the £ coli strain comprises lactyl-CoA dehydratase activity and 3-hydroxypropionyl-CoA dehydratase activity.
  • the £ coli strain produces one or more of the following polypeptides: a polypeptide having E1 activator activity; an E2 alpha polypeptide that is a subunit of an enzyme having lactyl-CoA dehydratase activity; an E2. beta polypeptide that is a subunit of an enzyme having lacty- CoA dehydratase activity; and a polypeptide having 3-hydroxypropionyl-CoA dehydratase activity.
  • the strain can have CoA transferase activity, CoA synthetase activity, polyhydroxyacid synthase activity, 3-hydroxypropionyl-CoA hydrolase activity, 3-hydroxyisobutryl-CoA hydrolase activity, alanine dehydrogenase, alanine aminotransferase, alanine 2,3-aminom ⁇ rtase, and/or lipase activity.
  • coli strain can contain at least one foreign polynucleotide that encodes one or more polypeptides that have CoA transferase activity, 3-hydroxypropionyl-CoA hydrolase activity, 3-hydroxyisobutryl-CoA hydrolase activity, CoA synthetase activity, polyhydroxyacid synthase activity, alanine dehydrogenase, alanine aminotransferase, alanine 2,3-aminomutase, and/or lipase activity.
  • the E. coli strain comprising, for example, lactyl-CoA dehydratase activity and 3-hydroxypropionyl-CoA dehydratase activity produces a product, for example, 3HP, polymerized 3HP, and/or an ester of 3HP, such as methyl hydroxypropionate, ethyl hydroxypropionate, propyl hydroxypropionate, and/or butyl hydroxypropionate.
  • the present invention also provides methods of producing one or more of these products. These methods involve culturing the E. coli strain comprising, for example, lactyl-CoA dehydratase activity and 3-hydroxypropionyl- CoA dehydratase activity under conditions that allow the product to be produced.
  • These strains also can have, for example, CoA synthetase activity and/or polyhydroxyacid synthase activity.
  • the E.. coli strain comprises CoA synthetase activity, lactyl- CoA dehydratase activity, and polyhydroxyacid synthase activity for production of polymerized acrylate.
  • these cells also can comprise a foreign polynucleotide that encodes one or more of the following polypeptides: a polypeptide having E1 activator activity; an E2.
  • the E. coli strain comprises CoA transferase activity, lactyl-CoA dehydratase activity, and lipase activity.
  • the strain also can comprise a foreign polynucleotide that encodes one or more of the following polypeptides: a polypeptide having CoA transferase activity; a polypeptide having E1 activator activity; an E2 alpha polypeptide that is a subunit of an enzyme having lactyl-CoA dehydratase activity; an E2 beta polypeptide that is a subunit of an enzyme having lactyl-CoA dehydratase activity; and a polypeptide having lipase activity.
  • a strain can be used, for example, to produce products such as esters of acrylate (e.g., methyl acrylate, ethyl acrylate, propyl acrylate, and butyl acrylate).
  • a foreign polynucleotide can be introduced into an E. coli cell using any method known in the art such as protoplast transformation (see, e.g., Hanahan, 1983, J. MoI. Biol. 166: 557-580) or electroporation (see, e.g., Dower ef a/., 1988, Nucleic Adds Res. 16: 6127-6145).
  • protoplast transformation see, e.g., Hanahan, 1983, J. MoI. Biol. 166: 557-580
  • electroporation see, e.g., Dower ef a/., 1988, Nucleic Adds Res. 16: 6127-6145.
  • the E. coli strains and polypeptides having enzyme activity described herein can be used to produce 3HP and/or other organic compounds derived from 3HP such as 1 ,3-propanediol, acrylic acid, polymerized acrylate, esters of acrylate, esters of 3HP, and polymerized 3HP. Consequently, the present invention also relates to methods for producing 3HP and compounds derived from 3HP via lactate, phosphoenolpyruvate, pyruvate, acetyl-CoA, propionyl-CoA, or beta-alanine as intermediates. These methods involve culturing an E. coli strain comprising at least one foreign polynucleotide that encodes at least one polypeptide such that 3HP is produced.
  • 3HP is produced by culturing the E. coli strain in a culture medium such that 3HP is produced.
  • the culture media and/or culture conditions can be such that the microorganisms grow to an adequate density and produce 3HP efficiently.
  • any method can be used such as those described elsewhere (Manual of Industrial Microbiology and Biotechnology, 2 nd Edition, Editors: A. L. Demain and J. E. Davies, ASM Press; and Principles of Fermentation Technology, P. F. Stanbury and A. Whitaker, Pergamon).
  • a large tank ⁇ e.g., a 100 gallon, 200 gallon, 500 gallon, or more fermentation tank) containing appropriate culture medium with, for example, glucose as a carbon source is inoculated with a particular microorganism. After inoculation, the microorganisms are incubated to allow biomass to be produced. Once a desired biomass is reached, the broth containing the microorganisms can be transferred to a second tank.
  • This second tank can be any size.
  • the second tank can be larger, smaller, or the same size as the first tank.
  • the second tank is larger than the first such that additional culture medium can be added to the broth from the first tank.
  • the culture medium within this second tank can be the same as, or different from, that used in the first tank.
  • the first tank can contain medium with xylose, while the second tank contains medium with glucose.
  • the microorganisms can be incubated to allow for the production of 3HP.
  • any method can be used to isolate the 3HP.
  • common separation techniques can be used to remove the biomass from the broth, and common isolation procedures (e.g., extraction, distillation, and ion-exchange procedures) can be used to obtain the 3HP from the microorganism-free broth.
  • 3HP can be isolated while it is being produced, or it can be isolated from the broth after the product production phase has been terminated. If 3HP and/or the other organic compounds derived from 3HP are secreted into the nutrient medium, the products can be recovered directly from the medium. If the products are not secreted into the medium, they can be can be recovered from cell lysates.
  • cells are separated and collected from a culture of transformed cells; processed transformed cells are subjected to acetone treatment or lyophilization; a cell-free extract is prepared from such transformed microorganism cells or processed cells; fractions such as membrane fractions are fractioned from such cell-free extract; or immobilized materials can be produced by immobilizing transformed microorganism cells, processed cells, cell-free extract and fractions, any of which independently or combined contacted with sucrose and/or glucose to produce 3HP.
  • the microorganism can consist of one kind of microorganism, or can be used as an arbitrary mixture of two or more kinds of microorganisms.
  • 3HP Growth and production of 3HP can be performed in normal batch fermentations, fed-batch fermentations or continuous fermentations. In certain aspects, it is desirable to perform fermentations under reduced oxygen or anaerobic conditions for certain hosts. In other aspects, 3HP production can be performed with oxygen; and, optionally with the use of air-lift or equivalent fermentors.
  • Fermentation parameters are dependent on the E.. coli strain used for production of the recombinant enzyme.
  • Cultivation of the metabolically engineered E. coli strains of the present invention is preferably performed under aerobic or anaerobic conditions for about 0.5 to 240 hours.
  • the cultivation temperature is preferably controlled at about 25°C to 45°C, and pH is preferably controlled at 5-8 during cultivation.
  • Inorganic or organic, acidic, or alkaline substances as well as ammonia gas or the like can be used for pH adjustment.
  • 3HP can be removed continuously during the fermentation using methods such as membrane technology, electro-dialysis, solvent extraction, and absorbent resins.
  • membrane technology electro-dialysis, solvent extraction, and absorbent resins.
  • Growth medium may be minimal/defined or complete/complex.
  • Fermentable carbon sources could include hexose and pentose sugars (e.g., ribose, arabinose, xylose, and lyxose), starch, cellulose, xylan, oligosaccharides, and combinations thereof.
  • examples of carbohydrates that cells are capable of metabolizing to pyruvate include sugars such as dextrose, triglycerides, and fatty acids.
  • One form of growth media that can be used in accordance with the subject invention includes modified Luria-Bertani (LB) broth (with 10 g Difco tryptone, 5 g Difco yeast extract, and 5 g sodium chloride per liter) as described by Miller, 1992, A Short Course in Bacterial Genetics: A Laboratory Manual and Handbook for Escherichia coli and Related Bacteria, Cold Spring Harbor Press.
  • LB Luria-Bertani
  • cultures of metabolically engineered E. coli strains of the present invention can be grown in NBS mineral salts medium (as described by Causey et al., 2004, Proc. Natl. Acad. Sd.
  • NBS mineral salts medium comprises, consists essentially of, or consists of the following components (per liter): 3.5 g of KH 2 PO 4 ; 5.0 g of K 2 HPO 4 ; 3.5 g of (NH 4 ) 2 HPO 4 ; 0.25 g of MgSO 4 -7H 2 O; 15 mg CaCI 2 ⁇ 2H 2 O; 0.5 mg of thiamine; and 1 ml of trace metal stock, glucose (e.g., 2% in plates or 3% in broth), and 1.5% agar (for plates).
  • the trace metal stock is prepared in 0.1 M HCI and comprises, consists essentially of, or consists of (per liter): 1.6 g of FeCI 3 ; 0.2 g of CoCI 2 -6H 2 O; 0.1 g of CuCI 2 ; 0.2 g of ZnCI 2 -4H 2 O; 0.2 g of NaMoO 4 ; and 0.05 g of H 3 BO 3 .
  • 4-Morpholinopropanesulfonic acid (0.1 M, pH 7.1) can be added to both liquid and solid media (filter-sterilized) when needed for pH control (and is optionally included in medium used for 10-liter fermentations).
  • Minimal medium can also be prepared by using succinate (1 g/liter) as a sole source of carbon (nonfermentable substrate) and can be added as a supplement to glucose-minimal medium when needed. In certain aspects, antibiotics can be included as needed.
  • the methods produce 3HP via pyruvate through lactate by engineering the metabolic steps leading from pyruvate to 3HP to allow for unimpeded flow of intermediates from pyruvate to 3HP as shown in Figure 1.
  • the methods produce 3HP via pyruvate through acetyl-CoA by engineering the metabolic steps leading from pyruvate to 3HP to allow for unimpeded flow of intermediates from pyruvate to 3HP as shown in Figure 4.
  • the methods produce 3HP from propionate through propionyl- CoA and acrylyl-CoA by engineering the metabolic steps leading from pyruvate to 3HP to allow for unimpeded flow of intermediates from propionate to 3HP as shown in Figure 5.
  • the methods produce 3HP via phosphoenolpyruvate or pyruvate through beta-alanine and acrylyl-CoA by engineering the metabolic steps leading from phosphoenolpyruvate or pyruvate to 3HP to allow for unimpeded flow of intermediates from phosphoenolpyruvate or pyruvate to 3HP as shown in Figure 6.
  • the methods produce 3HP via phosphoenolpyruvate or pyruvate through beta-alanine and malonate semialdehyde by engineering the metabolic steps leading from phosphoenolpyruvate or pyruvate to 3HP to allow for unimpeded flow of intermediates from phosphoenolpyruvate or pyruvate to 3HP as shown in Figure 7.
  • the methods produce 3HP wherein lactate is contacted with a first polypeptide having CoA trasferase activity or CoA synthetase activity such that lactyl-CoA is formed, then contacting lactyl-CoA with a second polypeptide having lactyl- CoA dehydratase activity to form acrylyl-CoA, then contacting acrylyl-CoA with a third polypeptide having 3-hydroxypropionyl-CoA dehydratase activity to form 3-hydroxypropionic acid-CoA, and then contacting 3-hydroxypropionic acid-CoA with the first polypeptide to form 3HP or with a fourth polypeptide having 3-hydroxypropionyl-CoA hydrolase activity or 3-hydroxyisobutryl-CoA hydrolase activity to form 3HP.
  • the methods produce polymerized 3HP. These methods involve producing 3-hydroxypropionic acid-CoA as described herein, and then contacting the 3-hydroxypropionic acid-CoA with a polypeptide having polyhydroxyacid synthase activity to form polymerized 3HP. In another aspect, the methods produce an ester of 3HP. These methods involve producing 3HP as described herein, and then additionally contacting 3HP with a fifth polypeptide having lipase activity to form an ester.
  • the organic compounds produced from any of the steps provided in Figures 1-7 can be chemically converted into other organic compounds.
  • 3HP can be hydrogenated to form 1 ,3-propanediol, a valuable polyester monomer.
  • Hydrogenating an organic acid such as 3HP can be performed using any method such as those used to hydrogenate succinic acid and/or lactic acid.
  • 3HP can be hydrogenated using a metal catalyst.
  • 3HP can be dehydrated to form acrylic acid. Any method can be used to perform a dehydration reaction.
  • 3HP can be heated in the presence of a catalyst ⁇ e.g., a metal or mineral acid catalyst) to form acrylic acid.
  • a catalyst ⁇ e.g., a metal or mineral acid catalyst
  • Propanediol also can be obtained using polypeptides having oxidoreductase activity (e.g. , enzymes is the 1.1.1.- class of enzymes) in vitro or in vivo.
  • the methods produce polymerized acrylate. These methods involve culturing a cell that has both CoA synthetase activity, lactyl-CoA dehydratase activity, and polyhydroxyacid synthase activity such that polymerized acrylate is produced.
  • the present invention also provides methods of producing polymerized acrylate wherein lactate is contacted with a first polypeptide having CoA synthetase activity to form lactyl-CoA, then contacting lactyl-CoA with a second polypeptide having lactyl-CoA dehydratase activity to form acrylyl-CoA, and then contacting acrylyl-CoA with a third polypeptide having polyhydroxyacid synthase activity to form polymerized acrylate.
  • the methods produce an ester of acrylate. These methods involve culturing an E. coli cell that has CoA transferase activity, lipase activity, and lactyl-CoA dehydratase activity under conditions that allow the cell to produce an ester.
  • the methods produce an ester of acrylate, wherein acrylyl- CoA is formed as described herein, and then acrylyl-CoA is contacted with a polypeptide having CoA transferase activity to form acrylate, and acrylate is contacted with a polypeptide having lipase activity to form the ester.
  • the methods produce 1,3-propanediol, which can be obtained from either 3HP-CoA or 3HP via the use of polypeptides having enzyme activity described herein. These polypeptides can be used either in vitro or in vivo.
  • polypeptides having oxidoreductase activity or reductase activity e.g., enzymes from the 1.1.1. -class of enzymes
  • oxidoreductase activity or reductase activity e.g., enzymes from the 1.1.1. -class of enzymes
  • a combination of (1) a polypeptide having aldehyde dehydrogenase activity (e.g., an enzyme from the 1.1.1.34 class) and (2) a polypeptide having alcohol dehydrogenase activity (e.g., an enzyme from the 1.1.1.32 class) can be used.
  • the methods produce 3HP or a compound derived from 3HP in a concentration of at least about 100 mg per L (e.g., at least about 1 g/L, 5 g/L, 10 g/L, 25 g/L, 50 g/L, 75 g/L, 80 g/L, 90 g/L, 100 g/L, 120 g/L or 130 g/L).
  • any method can be used. See, e.g., Applied Environmental Microbiology 59: 4261-4265 (1993) and Sullivan and Clarke, 1955, J. Assoc. Offic. Agr. Chemists, 38: 514-518.
  • the purified polypeptides having enzyme activity described herein can be used alone or in combination with cells to produce 3HP or other organic compounds such as 1 ,3-propanediol, acrylic acid, polymerized acrylate, esters of acrylate, esters of 3HP, and polymerized 3HP.
  • a preparation containing a substantially pure polypeptide having 3-hydroxypropionyl-CoA dehydratase activity can be used to catalyze the formation of 3HP-CoA, a precursor to 3HP.
  • cell-free extracts containing a polypeptide having enzyme activity can be used alone or in combination with purified polypeptides and/or cells to produce 3HP.
  • a cell-free extract containing a polypeptide having CoA transferase activity can be used to form lactyl-CoA, while a microorganism containing polypeptides have the enzyme activities necessary to catalyze the reactions needed to form 3HP from lactyl-CoA can be used to produce 3HP.
  • Any method can be used to produce a cell-free extract. For example, osmotic shock, sonication, and/or a repeated freeze-thaw cycle followed by filtration and/or centrifugation can be used to produce a cell-free extract from intact cells.
  • 3HP produced by a metabolically engineered E. coli strain, purified polypeptide, and/or cell-free extract can be treated chemically to produce another compound.
  • a microorganism can be used to produce 3HP, while a chemical process is used to modify 3HP into a derivative such as polymerized 3HP or an ester of 3HP.
  • a chemical process can be used to produce a particular compound that is converted into 3HP or other organic compound (e.g., 1,3-propanediol, acrylic acid, polymerized acrylate, esters of acrylate, esters of 3HP, and polymerized 3HP) using a cell, substantially pure polypeptide, and/or cell-free extract described herein.
  • a chemical process can be used to produce acrylyl-CoA, while a microorganism can be used convert acrylyl-CoA into 3HP.
  • Example 1 Inactivation of the IdhA gene or the cloned Geobacillus stearothermophilus alaD gene in high lactic acid-producing or high alanine- producing strains of E. coli
  • the starting Escherichia coli strains for further genetic manipulation include, but are not limited to, SZ32, SZ37, SZ40, SZ58. SZ63, LY52, SZ110, SZ132, SZ136, SZ162, SZ186, SZ194, TG102, TG103, TG105, TG106, TG107, TG108, TG112, TG113, TG114, TG128, TG129, TG130, XZ103, XZ104.
  • modifications to the IdhA gene locus are one or more mutations, deletions, insertions, or substitutions and are achieved using any of a number of established E. coli genetic modification methods that are well known in the art. For example, deletion of the IdhA gene is achieved using the method of Datsenko and Wanner (2000, Proc. Natl. Acad. Sd. 97: 6640-6645), while insertion or gene substitution is achieved using essentially the same procedure used by Zhang et al.,
  • IdhA promoter sequence is inactivated using the same well-known E. coli genetic methods as used for inactivation of the IdhA gene (Datsenko and Wanner, 2000, supra).
  • the resulting strains in which the IdhA gene or Geobacillus stearothermophilus alaD gene is inactivated retain all other properties that contribute to high lactic acid or alanine production when the IdhA or Geobacillus stearothermophilus alaD gene are functional.
  • Cloning of genes required for 3HP production and introduction of the cloned DNA into any of the E. coli strains listed in Example 1 is performed using standard techniques known to one skilled in the art (J. Sambrook, E.F. Fritsch, and T. Maniatis, 1989, Molecular Cloning, A Laboratory Manual, 2d edition, Cold Spring Harbor, New York). Cloned genes may be introduced into any of the E. coli strains listed in Example 1 in the form of replicating plasmids or may be integrated at any site in the E. coli genome (Datsenko and Wanner, 2000, supra), which does not result in a non-viable strain. Expression of the cloned genes required for 3HP production in any of the E.
  • Example 1 is achieved using any DNA sequence that promotes expression of the cloned gene in any of the £ coli strains listed in Example 1.
  • expression of the desired cloned genes may be achieved by cloning the genes under genetic regulatory control of promoters that effect gene expression in E. coli such as, but not limited to, the lac, tac, araB, trp, trc, amyE, spac, or lambda phage PL or PR promoters.
  • Cloned genes required for 3HP production can also be cloned under control of native or genetically modified E.
  • Example 3 Improving 3HP-producing E. coli strains by random or targeted mutagenesis procedures 3HP-Producing E. coli strains obtained as described in Example 2 are further improved by random or targeted mutagenesis procedures (Reidhaar-Olson and Sauer, 1988, Science 241 : 53-57; Bowie and Sauer, 1989, Proc. Natl. Acad. Sd. USA 86: 2152-2156; WO 95/17413; WO 95/22625; Lowman et al., 1991, Biochem. 30: 10832- 10837; U.S. Patent No.
  • any of the high lactic acid- or alanine-producing strains listed in Example 1 and modified to produce 3HP by any of the methods described in Example 2 is treated with chemicals such as N-methyl-N'-nitro-N-nitrosoguanidine or ethyl methane sulfonate, or treated with ultraviolet radiation, to cause mutations in the strain's genetic material.
  • the E. coli strains are subjected to, for example, transposon mutagenesis using methods well known to one skilled in the art. Following the mutagenic treatment, the population of E. coli cells is screened for cells having improved 3HP production compared to the parental E. coli strain (i.e., the unmutagenized strain).
  • the resulting 3HP-producing mutants retain all properties that contribute to high lactic acid or alanine production when the IdhA or Geobacillus st ⁇ arothermophilus alaD gene is functional compared to when the genes required for 3HP production are not introduced and/or there is no mutagenesis.
  • any of the E. coli strains described in Example 2 or 3 is achieved by cultivating the cells in any medium and under any cultivation conditions that allow growth of the E. coli strains described in Examples 1 , 2 or 3.
  • any of the E. coli strains described in Examples 1 , 2 or 3 are cultivated in a nutrient-rich medium such as Luria-Bertani (LB) broth or nutrient broth, or in a chemically defined medium such as (but not limited to) NBS mineral salts medium (Causey et al., 2004, supra).
  • the carbon source used for growth in any mineral salts medium is glucose, sucrose, pentoses or any other carbon source that supports the growth of E. coli.
  • the carbon sources may be well established commercially available compositions such as dextrose syrup, or may be present in mixtures obtained following physical, chemical and/or enzymatic degradation of lignocellulosic biomass.
  • the cultivation conditions including but not limited to, time, temperature, pH, oxygen supply (anaerobic, aerobic or minimally aerobic conditions) and stirring, may be varied in any way provided that the conditions allow growth of the 3HP-producing E. coli strains.
  • Growth and production of 3HP using any of the £ coli strains described in Examples 2 or 3 may be performed in batch, fed-batch, or continuous cultivation processes, and may be performed with or without addition of osmoprotectants such as, but not limited to, betaine, to the cultivation medium.
  • the £ coli strains described in Examples 2 and 3 are able produce 3HP in the cultivation medium at concentrations and yields similar to the lactic acid or alanine production in the lactic acid- or alanine-producing strains from which they were derived.
  • 3HP concentration in the culture broth ranges from 0.5 M to 1.3 M
  • the yield of 3HP (based on substrate, e.g., glucose, consumed) ranges from 80% to 99%.
  • Co-products such as succinic acid, acetate and ethanol, if produced, are produced at concentrations below 100 mM.
  • Example 5 Analysis of cell mass, organic acids, sugars and other compounds present in cultivation broths
  • Cell mass of any of the E. coli strains described in Example 1 , 2 or 3 are measured using any of a number of methods well known in the art, such as measurement of optical density and measurement of cell dry weight.
  • Organic acids, sugars, and other compounds are measured in the cultures of any of the E. coli strains described in Example 1 , 2 or 3, grown as described in Example 4, using analytical techniques that are well known in the art. For example, organic acids, and sugars are measured by high performance liquid chromatography (Zhou et al., 2003, supra) or by ultraperformance liquid chromatography-tandem mass spectrometry (Ross et al., 2007, Anal. Chem. 79: 4840-4844) while ethanol is measured by gas chromatography, as described, for example, by Zhou et al., 2003, supra.
  • Example 6 Recovery of 3HP from culture broth
  • the 3HP present in the culture broth is recovered by any method known in the art including, but not limited to, acidification of the broth with a mineral acid, such as sulfuric acid, to allow recovery of the 3HP with calcium sulfate as a byproduct (WO 2002/090312), extraction of 3HP using organic solvents (WO 2002/090312, WO 2005/003074, WO 2005/021470), or electrodilaysis.

Landscapes

  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne des procédés permettant de produire de l'acide 3-hydroxypropionique (3HP). Lesdits procédés consistent à cultiver une souche de E. coli métaboliquement modifiée issue d'une souche préalablement modifiée pour une production élevée d'acide lactique ou de L-alanine, la souche de E. coli métaboliquement modifiée produisant de l'acide 3-hydroxypropionique (3HP).
PCT/US2009/030607 2008-01-11 2009-01-09 Procédés pour produire de l'acide 3-hydroxypropionique et composés correspondants WO2009089457A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2051408P 2008-01-11 2008-01-11
US61/020,514 2008-01-11

Publications (1)

Publication Number Publication Date
WO2009089457A1 true WO2009089457A1 (fr) 2009-07-16

Family

ID=40565220

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/030607 WO2009089457A1 (fr) 2008-01-11 2009-01-09 Procédés pour produire de l'acide 3-hydroxypropionique et composés correspondants

Country Status (1)

Country Link
WO (1) WO2009089457A1 (fr)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010084947A1 (fr) * 2009-01-23 2010-07-29 中外製薬株式会社 Procédé de production de polypeptide hétérologue
GB2473755A (en) * 2009-09-27 2011-03-23 Opx Biotechnologies Inc Method for producing 3-hydroxypropionic acid and acrylic acid
US8541212B2 (en) 2011-06-27 2013-09-24 Samsung Electronics Co., Ltd. Genetic modification for production of 3-hydroxypropionic acid
WO2013180581A1 (fr) * 2012-05-30 2013-12-05 Lanzatech New Zealand Limited Micro-organismes recombinants et leurs utilisations
US8728788B1 (en) 2011-09-30 2014-05-20 Novozymes A/S Dehydrogenase variants and polynucleotides encoding same
WO2014062556A3 (fr) * 2012-10-15 2014-06-12 The Procter & Gamble Company Microorganismes et procédés pour la production d'acrylate et d'autres produits à partir de propionyl-coa
WO2014145297A1 (fr) * 2013-03-15 2014-09-18 Opx Biotechnologies, Inc. Procédé de bioproduction améliorée
US9090918B2 (en) 2010-11-22 2015-07-28 Novozymes A/A Compositions and methods for 3-hydroxypropionic acid production
KR20150130830A (ko) * 2014-05-14 2015-11-24 삼성전자주식회사 신규한 아크릴산 생성 경로를 갖는 미생물 및 이를 이용한 아크릴산 생산 방법
US9365875B2 (en) 2012-11-30 2016-06-14 Novozymes, Inc. 3-hydroxypropionic acid production by recombinant yeasts
US10047383B2 (en) 2013-03-15 2018-08-14 Cargill, Incorporated Bioproduction of chemicals
US10337038B2 (en) 2013-07-19 2019-07-02 Cargill, Incorporated Microorganisms and methods for the production of fatty acids and fatty acid derived products
US10465213B2 (en) 2012-08-10 2019-11-05 Cargill, Incorporated Microorganisms and methods for the production of fatty acids and fatty acid derived products
US10494654B2 (en) 2014-09-02 2019-12-03 Cargill, Incorporated Production of fatty acids esters
US11345938B2 (en) 2017-02-02 2022-05-31 Cargill, Incorporated Genetically modified cells that produce C6-C10 fatty acid derivatives
US11408013B2 (en) 2013-07-19 2022-08-09 Cargill, Incorporated Microorganisms and methods for the production of fatty acids and fatty acid derived products
WO2022251933A1 (fr) * 2021-06-01 2022-12-08 Braskem S.A. Production de semialdéhyde malonate et dérivés par des micro-organismes exprimant l'aspartate 1-décarboxylase
US11788092B2 (en) 2021-02-08 2023-10-17 Lanzatech, Inc. Recombinant microorganisms and uses therefor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002042418A2 (fr) * 2000-11-20 2002-05-30 Cargill, Incorporated Acide 3-hydroxypropionique et autres composes organiques
DE102005048818A1 (de) * 2005-10-10 2007-04-12 Degussa Ag Mikrobiologische Herstellung von 3-Hydroxypropionsäure
WO2008027742A1 (fr) * 2006-08-30 2008-03-06 Cargill, Incorporated Bêta-alanine/alpha-cétoglutarate aminotransférase pour la production d'acide3-hydroxypropionique

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002042418A2 (fr) * 2000-11-20 2002-05-30 Cargill, Incorporated Acide 3-hydroxypropionique et autres composes organiques
DE102005048818A1 (de) * 2005-10-10 2007-04-12 Degussa Ag Mikrobiologische Herstellung von 3-Hydroxypropionsäure
WO2008027742A1 (fr) * 2006-08-30 2008-03-06 Cargill, Incorporated Bêta-alanine/alpha-cétoglutarate aminotransférase pour la production d'acide3-hydroxypropionique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ISHII M ET AL: "Occurrence, biochemistry and possible biotechnological application of the 3-hydroxypropionate cycle.", APPLIED MICROBIOLOGY AND BIOTECHNOLOGY JUN 2004, vol. 64, no. 5, June 2004 (2004-06-01), pages 605 - 610, XP002526381, ISSN: 0175-7598 *

Cited By (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010084947A1 (fr) * 2009-01-23 2010-07-29 中外製薬株式会社 Procédé de production de polypeptide hétérologue
US8883464B2 (en) 2009-09-27 2014-11-11 Opx Biotechnologies, Inc. Methods for producing 3-hydroxypropionic acid and other products
GB2473755A (en) * 2009-09-27 2011-03-23 Opx Biotechnologies Inc Method for producing 3-hydroxypropionic acid and acrylic acid
GB2473755B (en) * 2009-09-27 2011-09-07 Opx Biotechnologies Inc Method for producing 3-hydroxypropionic acid and other products
US9428778B2 (en) 2009-09-27 2016-08-30 Cargill, Incorporated Method for producing 3-hydroxypropionic acid and other products
US9388419B2 (en) 2009-09-27 2016-07-12 Cargill, Incorporated Methods for producing 3-hydroxypropionic acid and other products
US10100342B2 (en) 2009-09-27 2018-10-16 Cargill, Incorporated Method for producing 3-hydroxypropionic acid and other products
JP2016036346A (ja) * 2009-09-27 2016-03-22 オーピーエックス バイオテクノロジーズ， インコーポレイテッド ３−ヒドロキシプロピオン酸および他の生成物を生成するための方法
EP2480673A4 (fr) * 2009-09-27 2014-10-08 Opx Biotechnologies Inc Procédé de production d'acide 3-hydroxypropionique et d'autres produits
US10633664B2 (en) 2010-11-22 2020-04-28 Cargill, Incorporated Compositions and methods for 3-hydroxypropionic acid production
US11118187B2 (en) 2010-11-22 2021-09-14 Cargill, Incorporated Compositions and methods for 3-hydroxypropionic acid production
US9090918B2 (en) 2010-11-22 2015-07-28 Novozymes A/A Compositions and methods for 3-hydroxypropionic acid production
US10260072B2 (en) 2010-11-22 2019-04-16 Cargill, Incorporated Compositions and methods for 3-hydroxypropionic acid production
CN107828671B (zh) * 2010-11-22 2022-03-08 卡吉尔公司 用于生产3-羟基丙酸的组合物和方法
US12054721B2 (en) 2010-11-22 2024-08-06 Cargill, Incorporated Compositions and methods for 3-hydroxypropionic acid production
CN107828671A (zh) * 2010-11-22 2018-03-23 卡吉尔公司 用于生产3‑羟基丙酸的组合物和方法
US8541212B2 (en) 2011-06-27 2013-09-24 Samsung Electronics Co., Ltd. Genetic modification for production of 3-hydroxypropionic acid
US9163220B2 (en) 2011-09-30 2015-10-20 Novozymes A/S Dehydrogenase variants and polynucleotides encoding same
US8728788B1 (en) 2011-09-30 2014-05-20 Novozymes A/S Dehydrogenase variants and polynucleotides encoding same
US9404091B2 (en) 2011-09-30 2016-08-02 Novozymes, Inc. Dehydrogenase variants and polynucleotides encoding same
US9994878B2 (en) 2012-05-30 2018-06-12 Lanzatech New Zealand Limited Recombinant microorganisms and uses therefor
WO2013180581A1 (fr) * 2012-05-30 2013-12-05 Lanzatech New Zealand Limited Micro-organismes recombinants et leurs utilisations
CN104508136A (zh) * 2012-05-30 2015-04-08 新西兰郎泽科技公司 重组微生物及其用途
US10465213B2 (en) 2012-08-10 2019-11-05 Cargill, Incorporated Microorganisms and methods for the production of fatty acids and fatty acid derived products
WO2014062556A3 (fr) * 2012-10-15 2014-06-12 The Procter & Gamble Company Microorganismes et procédés pour la production d'acrylate et d'autres produits à partir de propionyl-coa
US9365875B2 (en) 2012-11-30 2016-06-14 Novozymes, Inc. 3-hydroxypropionic acid production by recombinant yeasts
WO2014145297A1 (fr) * 2013-03-15 2014-09-18 Opx Biotechnologies, Inc. Procédé de bioproduction améliorée
US10155937B2 (en) 2013-03-15 2018-12-18 Cargill, Incorporated Acetyl-CoA carboxylases
US10047383B2 (en) 2013-03-15 2018-08-14 Cargill, Incorporated Bioproduction of chemicals
US10815473B2 (en) 2013-03-15 2020-10-27 Cargill, Incorporated Acetyl-CoA carboxylases
US10337038B2 (en) 2013-07-19 2019-07-02 Cargill, Incorporated Microorganisms and methods for the production of fatty acids and fatty acid derived products
US11408013B2 (en) 2013-07-19 2022-08-09 Cargill, Incorporated Microorganisms and methods for the production of fatty acids and fatty acid derived products
US12129506B2 (en) 2013-07-19 2024-10-29 Cargill, Incorporated Microorganisms and methods for the production of fatty acids and fatty acid derived products
KR102208963B1 (ko) * 2014-05-14 2021-01-28 삼성전자주식회사 신규한 아크릴산 생성 경로를 갖는 미생물 및 이를 이용한 아크릴산 생산 방법
KR20150130830A (ko) * 2014-05-14 2015-11-24 삼성전자주식회사 신규한 아크릴산 생성 경로를 갖는 미생물 및 이를 이용한 아크릴산 생산 방법
US10494654B2 (en) 2014-09-02 2019-12-03 Cargill, Incorporated Production of fatty acids esters
US11345938B2 (en) 2017-02-02 2022-05-31 Cargill, Incorporated Genetically modified cells that produce C6-C10 fatty acid derivatives
US12123045B2 (en) 2017-02-02 2024-10-22 Cargill, Incorporated Genetically modified cells that produce C6-C10 fatty acid derivatives
US11788092B2 (en) 2021-02-08 2023-10-17 Lanzatech, Inc. Recombinant microorganisms and uses therefor
WO2022251933A1 (fr) * 2021-06-01 2022-12-08 Braskem S.A. Production de semialdéhyde malonate et dérivés par des micro-organismes exprimant l'aspartate 1-décarboxylase

Similar Documents

Publication Publication Date Title
WO2009089457A1 (fr) Procédés pour produire de l'acide 3-hydroxypropionique et composés correspondants
US11365432B2 (en) Adipate (ester or thioester) synthesis
US20200255840A1 (en) High yield route for the production of 1, 6-hexanediol
KR101930540B1 (ko) 아디페이트, 헥사메틸렌디아민 및 6-아미노카프로산의 생합성을 위한 미생물 및 방법
US9034615B2 (en) Glycolic acid production by fermentation from renewable resources
US20120244588A1 (en) Method of producing 3-hydroxypropionic acid using malonic semialdehyde reducing pathway
EP3027733B1 (fr) Production d'acide 3-hydroxypropionique par des levures recombinantes exprimant une aspartate 1-décarboxylase d'insecte
US11124778B2 (en) Process and microorganism for synthesis of adipic acid from carboxylic acids
CN113528417A (zh) 生产1,4-丁二醇的微生物和相关方法
KR20120083908A (ko) 1,4-부탄다이올, 4-하이드록시부탄알, 4-하이드록시부티릴-ｃｏａ, 푸트레신 및 관련 화합물의 제조를 위한 미생물 및 관련 방법
EP2925873B1 (fr) Production d'acide 3-hydroxypropionique par des levures recombinantes
JP7625070B2 (ja) 組換え微生物及びｃ６化合物の製造方法
CN114341344A (zh) 用于改进醛脱氢酶活性的工程微生物体和方法
WO2018203076A1 (fr) Micro-organismes modifiés et procédés de production de composés carbonés en c5 ramifiés
US12104160B2 (en) Production of 4,6-dihydroxy-2-oxo-hexanoic acid
US12031123B2 (en) Recombinant bacterial cells and methods for producing poly(3-hydroxybutyrate-co-3-hydroxyvalerate)
Zheng et al. Enhanced 4-hydroxybutyrate incorporation into the PHA terpolymer of Haloferax mediterranei by heterologous expression of 4-hydroxybutyrate-CoA transferases/synthetases
AU2017213461B2 (en) Adipate (ester or thioester) synthesis
JP2024092581A (ja) カルボン酸生産能を有する好塩性の組換え微生物
WO2024033603A1 (fr) Procédé de production biologique d'acide méthacrylique et de dérivés de celui-ci

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09700991

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09700991

Country of ref document: EP

Kind code of ref document: A1